Relaxin-FOLFOX-IL-12 triple combination therapy engages memory response and achieves long-term survival in colorectal cancer liver metastasis
Authors:
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Journal of Controlled Release
- Vol. 319, 213-221
Abstract
No abstract availableKeywords
Funding Information
- NIH (DK100664, CA198999)
- Eshelman Institute for Innovation
This publication has 39 references indexed in Scilit:
- Relaxin gene delivery mitigates liver metastasis and synergizes with check point therapyNature Communications, 2019
- First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)European Journal of Cancer, 2017
- Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic CancerClinical Cancer Research, 2015
- Phase II Trial of Hepatic Artery Infusional and Systemic Chemotherapy for Patients With Unresectable Hepatic Metastases From Colorectal CancerAnnals of Surgery, 2015
- Antigen Availability Determines CD8+ T Cell-Dendritic Cell Interaction Kinetics and Memory Fate DecisionsImmunity, 2013
- Cytokine-Mediated Programmed Proliferation of Virus-Specific CD8+ Memory T CellsImmunity, 2013
- Rates and Patterns of Recurrence Following Curative Intent Surgery for Colorectal Liver MetastasisAnnals of Surgery, 2009
- Hepatic Stellate Cells Promote Liver Metastasis of Colon Cancer Cells by the Action of SDF-1/CXCR4 AxisAnnals of Surgical Oncology, 2009
- IL-12-Programmed Long-Term CD8+ T Cell Responses Require STAT4The Journal of Immunology, 2006
- Cytokine control of memory T-cell development and survivalNature Reviews Immunology, 2003